

Characterizing Oncogene Addiction in Alveolar Rhabdomyosarcoma to Find New Combination Therapies

Dissertation

zur

Erlangung der naturwissenschaftlichen Doktorwürde
(Dr. sc. nat.)

vorgelegt der

Mathematisch-naturwissenschaftlichen Fakultät

der

Universität Zürich

von

Johannes Ommer

aus

Deutschland

Promotionskommission

Prof. Dr. Beat Schäfer
(Vorsitz und Leitung der Dissertation)
Prof. Dr. Alessandro Sartori
PD Dr. Paolo Cinelli

Zürich, 2018

TABLE OF CONTENTS

1.	SUMMARY	1
2.	ZUSAMMENFASSUNG	2
3.	LIST OF ABBREVIATIONS	3
4.	INTRODUCTION	4
4.1	CANCER.....	4
4.1.1	General.....	4
4.1.2	Classification	5
4.1.3	Epidemiology.....	5
4.1.4	Etiology.....	5
4.1.5	Genomic and genetic alterations in cancer.....	6
4.1.6	Conventional therapy	6
4.1.6.1	Surgery and radiation	6
4.1.6.2	Chemotherapy	7
4.1.7	Targeted therapies	8
4.1.7.1	Small molecule kinase inhibitors	9
4.1.7.2	Non-kinase inhibitors.....	10
4.1.8	Immunotherapy.....	10
4.2	PEDIATRIC CANCER	12
4.2.1	Statistics adult vs. pediatric cancers.....	12
4.2.2	Etiology.....	12
4.2.3	Prognosis & therapy	13
4.3	RHABDOMYOSARCOMA	14
4.3.1	Subtypes and prognosis.....	15
4.3.2	Molecular characteristics	15
4.3.3	PAX-FOXO1 fusion genes.....	17
4.3.4	Therapy.....	18
4.3.5	Novel therapy approaches	19
4.3.5.1	Targeting PAX3-FOXO1 biology	21
4.4	CELL DEATH.....	22
4.4.1	General.....	22
4.4.2	Apoptosis.....	23
4.4.2.1	Characteristics	23
4.4.2.2	Intrinsic apoptosis.....	24
4.4.2.3	Extrinsic apoptosis	26
4.4.3	Necrosis / Necroptosis.....	26
4.4.4	Other modes of regulated cell death.....	27
4.4.5	Cell cycle control.....	27
4.4.5.1	Cellular senescence	28
4.4.5.2	Mitotic catastrophe	28
4.4.6	Therapeutic potential of cell death	29
4.4.6.1	BH3-mimetics	29
4.4.6.2	Immunogenic cell death	31
4.5	AURORA KINASES.....	31
4.5.1	Interactors.....	32
4.5.1.1	Positive regulators.....	32
	Aurora degradation.....	33

4.5.2 *Functions in cell cycle progression*..... 33

4.5.2.1 Centrosome maturation and separation 33

4.5.2.2 Mitotic entry / G2 checkpoint recovery..... 33

4.5.2.3 Bipolar spindle assembly / M checkpoint control..... 35

4.5.3 *Aurora Kinases in cancer* 36

4.5.3.1 Oncogenic potential of Aurora A 36

4.5.3.2 Interaction of Aurora A with tumor suppressors..... 36

4.5.3.3 Interaction of Aurora A with oncogenes..... 37

4.5.3.4 Aurora A as a therapeutic target in cancer 37

5. **AIM OF THE THESIS**..... 41

6. **RESULTS**..... 42

6.1 **MANUSCRIPT I** AURORA A KINASE INHIBITION DESTABILIZES MYCN AND PAX3-FOXO1 AND SYNERGIZES WITH NAVITOCCLAX TO CONTROL RHABDOMYOSARCOMA TUMOR GROWTH..... 43

6.2 **MANUSCRIPT II** MDM2 IS A PUTATIVE NOVEL TARGET GENE OF PAX3-FOXO1 IN ALVEOLAR RHABDOMYOSARCOMA AND CONTRIBUTES TO CELL SURVIVAL IN PATIENT-DERIVED XENOGRAFTS 90

7. **DISCUSSION** 115

7.1 THE ROLE OF NOXA IN PAX3-FOXO1 DEPENDENT CELL DEATH 115

7.2 REGULATION OF PAX3-FOXO1 STABILITY BY AURORA KINASE A..... 117

7.3 THE POTENTIAL OF CDK9 INHIBITION TO INTERFERE WITH PAX3-FOXO1..... 119

7.4 SYNERGISTIC EFFECTS OF AURORA KINASE A INHIBITION AND BH3-MIMETICS..... 120

7.5 THE ROLE OF AURORA KINASE A IN OTHER TRANSCRIPTION FACTOR DRIVEN CANCERS..... 121

7.6 THE ROLE OF MDM2 AS A POTENTIAL TARGET GENE OF PAX3-FOXO1 122

7.7 CONCLUSION..... 123

8. **REFERENCES** 124

9. **ACKNOWLEDGEMENTS**..... 148